Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

A groundbreaking clinical trial has revealed that nerve-stimulating therapy can bring significant improvements to people with ...

Treatment-resistant depression (TRD) occurs when major depressive disorder (MDD ... To discuss your depression treatment plan ...

A mental health professional familiar with cognitive remediation would be the best guide for group treatment. Do you live with major depressive disorder? Learn about the resources and protections ...

b For adolescents with major depressive disorder or if OCD, posttraumatic stress disorder, or generalized anxiety disorder is present. c First-line treatment if drug interactions with fluoxetine ...

Major depressive disorder ... remit following adequate antidepressant treatment, while most MDD patients suffer from significant core depressive or residual symptoms during their clinical course.

A thin wire connects the device to the left vagus nerve in the neck – a major nerve that serves as a communication highway ...

Vagus nerve stimulation therapy improved the symptoms of treatment-resistant depression for nearly 500 participants in a ...

People with severe, treatment-resistant depression who received a nerve-stimulating therapy showed significant improvement in ...

its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the Company's ...